- Adjusted EBITDA loss improved significantly by 58% to $3.6 million from $8.7 million in the prior year quarter.
- Cash and equivalents were $69.3 million at quarter end, with total liquidity of approximately $90.7 million including revolver access.
- Cash usage decreased by 55% in Q2 and 78% year-to-date compared to 2024, supporting a targeted 50% reduction for full year 2025.
- Gross margin slightly decreased to 79.7% from 80.2% in the prior year quarter.
- Net loss improved by 18% to $17.4 million or $0.28 per share from $21.2 million or $0.34 per share in Q2 2024.
- Operating expenses were reduced by 4% to $54.7 million compared to $57.1 million in Q2 2024 due to expense management initiatives.
- Revenue in Q2 2025 was $47.4 million, a 7% increase over Q2 2024, driven by higher bunion procedure kit sales.
Related items and other data are not available for this feed item.
Dafinchi